Cigna (CI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
UBS analysts have outlined a set of high-conviction healthcare ideas where they believed the market was underappreciating earnings durability and the scale of upcoming catalysts, focusing on stocks backed by differentiated views and proprietary insights. In biotechnology, they identified Cogent Biosciences (NASDAQ:COGT) as their top pick, arguing the company offered scarcity value as a SMID-cap advancing two late-stage, potentially blockbuster assets.
California Public Employees Retirement System trimmed its position in Cigna Group (NYSE: CI) by 9.0% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 690,200 shares of the health services provider's stock after selling 67,990 shares during the quarter. California Public
Ameriprise Financial Inc. boosted its position in Cigna Group (NYSE: CI) by 54.5% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,136,311 shares of the health services provider's stock after acquiring an additional 753,865 shares during the period. Ameriprise
CI trades below industry P/E as Evernorth growth, steady earnings beats and buybacks support outlook, though rising medical costs and debt remain key risks.
CVS Health (NYSE: CVS) and Cigna Group (NYSE: CI) are both major players in American healthcare.
The Medical-HMO industry leverages technology capabilities and M&A to fuel growth. Yet rising medical costs, workforce shortages and policy shifts pose roadblocks.
Cigna delivered another quarter of strong revenue and EPS beats, yet remains deeply discounted versus sector peers. CI's Evernorth Health Services segment drove 17% Q4 revenue growth, while aggressive buybacks and disciplined cost control supported EPS and margins. Management's conservative 2026 guidance appears intentionally low; I expect actual results to exceed both company and consensus forecasts.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
The Cigna Group Tuesday said long-time top executive David M. Cordani will retire as chief executive officer effective July 1, 2026, and be replaced by current president and chief operating officer Brian Evanko.